Unity Biotechnology Inc (NASDAQ:UBX) stock has reached a 52-week high, trading at $2.02, signaling a period of robust ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy ...

SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging ...

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic ...

NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that on January 6, 2025, the Compensation Committee of the Board of Directors ...

Stock analysts at Chardan Capital started coverage on shares of Unity Biotechnology (NASDAQ:UBX – Get Free Report) in a research note issued to investors on Friday, Marketbeat.com reports. The firm ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

(RTTNews) - Shares of Unity Biotechnology, Inc. (UBX) are gaining 9% in the pre-market trading after it has announced the appointment of Federico Grossi as Chief Medical Officer. Federico Grossi ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...